Translational Development Acquisition Corp.
TDAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $6,111 |
| Enterprise Value | $0 | $0 | $0 | $6,111 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -14.3% | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 15.1% | 27.4% | – |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | – | -115.3% | -155.2% | – |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | – | 846.5% | 662.5% | – |
| EPS Diluted | 0.08 | 0.074 | 0.37 | -0.002 |
| % Growth | 8% | -80% | 24,766.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |